Market Overview

Pfizer Settles Viagra Patent Litigation With Teva

Share:

Pfizer (NYSE: PFE) announced that it has settled its litigation against Teva
Pharmaceuticals, USA Inc., relating to Pfizer's patent covering the use
of Viagra® to treat erectile dysfunction (sildenafil…

Pfizer Inc. announced that it has settled its litigation against Teva
Pharmaceuticals, USA (NASDAQ: TEVA), relating to Pfizer's patent covering the use
of Viagra® to treat erectile dysfunction (sildenafil citrate 25, 50, and
100 mg tablets), which expires in April 2020 (including pediatric
exclusivity). As a result of the settlement, Teva will be allowed to
launch a generic version of Viagra® in the United States on December 11,
2017, or earlier under certain circumstances. Teva will pay Pfizer a
royalty for a license to produce its generic version. The terms of the
settlement agreement are otherwise confidential. Teva has received
tentative approval from the U.S. Food and Drug Administration (FDA) for
its generic version of Viagra®.

See full press release

Posted-In: News Guidance Offerings Contracts Buybacks Legal Management Global

 

Related Articles (TEVA + PFE)

View Comments and Join the Discussion!
Need corporate guidance data?
Click here to see licensing options.
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Ratio Long Call Spread

Northern Tier Refinery Workers Vote To Strike